

Environmental and Social Data Sheet

Overview

Project Name: *PERSONALISED IMMUNOTHERAPIES (EGFF)*
Project Number: *2018-0707*
Country: *Germany*
Project Description: *The promoter is a biotech company pioneering the development of next generation of personalised immunotherapies for oncology and other diseases. The project relates to R&D investments for the development of cancer patient-tailored therapeutic vaccines, based on break-through proprietary platforms.*

EIA required: no

Project included in Carbon Footprint Exercise¹: no

(details for projects included are provided in section: "EIB Carbon Footprint Exercise")

Environmental and Social Assessment

Environmental Assessment

The Promoter's investments that will be financed through this operation concern research, development and innovation activities carried out in the pharmaceutical sector, enabling the Company to develop and market a promising portfolio of innovative immuno-oncology therapeutics for the treatment of several malignant diseases. The Company's proprietary mRNA-based therapeutics have the potential to transform the treatment of oncological and non-oncological diseases (e.g. infectious diseases). The project does not require a full Environmental Impact Assessment (EIA) report: i) the research activities are not listed in any of the annexes of the related EU IEA Directive (2014/52/EU amending 2011/92/EU), and ii) the project will be carried out in existing facilities already authorised for similar activities and volumes.

The promoter's R&D facilities and practices are in compliance with relevant national and EU regulations and the promoter maintains adequate internal procedures and management practices. The use of animal testing is minimised and in line with the EU Directive 2010/63/EU. In addition, The Company has adequate policies and procedures in place to outsource and manage clinical trials in the different regions of the world in accordance with the EU 536/2014 regulation. The clinical trials which are sponsored by the project are performed under regulated and strictly controlled conditions, in existing specialised facilities which are regularly inspected by competent authorities - EMA in Europe and/or national equivalent bodies in the rest of the world (e.g. FDA).

¹ Only projects that meet the scope of the Carbon Footprint Exercise, as defined in the EIB Carbon Footprint Methodologies, are included, provided estimated emissions exceed the methodology thresholds: 20,000 tonnes CO₂e/year absolute (gross) or 20,000 tonnes CO₂e/year relative (net) – both increases and savings.

Luxembourg, 17.07.2019

Social Assessment, where applicable

If successful, the project is expected to lead to important social benefits stemming from its focus on the development of novel treatments for diseases associated with substantial social and economic impact, (e.g. melanoma, pancreatic cancer, triple negative breast cancer, etc.) in Europe and worldwide. By co-investing in this project, the Bank will contribute to making novel and better treatments available for such diseases.

Conclusions and Recommendations

If successful, the project presents potentially high health and societal benefits for the wider society. Considering the above, and the full compliance with all applicable EU Directives, Regulations and Standards across all business lines and processes, the project is deemed acceptable for the Bank's financing under environmental and social terms.

PJ/SQM/ECSO 01.02.2019